Top

Clinical Pharmacokinetics

Published in:

01-04-2003 | Review Article

Pharmacokinetics of Pegylated Liposomal Doxorubicin

Review of Animal and Human Studies

Authors: Alberto Gabizon, Hilary Shmeeda, Yechezkel Barenholz

Published in: Clinical Pharmacokinetics | Issue 5/2003

Abstract

Pegylated liposomal doxorubicin (doxorubicin HCl liposome injection; Doxil® or Caelyx®) is a liposomal formulation of doxorubicin, reducing uptake by the reticulo-endothelial system due to the attachment of polyethylene glycol polymers to a lipid anchor and stably retaining drug as a result of liposomal entrapment via an ammonium sulfate chemical gradient. These features result in a pharmacokinetic profile characterised by an extended circulation time and a reduced volume of distribution, thereby promoting tumour uptake.

Preclinical studies demonstrated one- or two-phase plasma concentration-time profiles. Most of the drug is cleared with an elimination half-life of 20–30 hours. The volume of distribution is close to the blood volume, and the area under the concentration-time curve (AUC) is increased at least 60-fold compared with free doxorubicin. Studies of tissue distribution indicated preferential accumulation into various implanted tumours and human tumour xenografts, with an enhancement of drug concentrations in the tumour when compared with free drug.

Clinical studies of pegylated liposomal doxorubicin in humans have included patients with AIDS-related Kaposi’s sarcoma (ARKS) and with a variety of solid tumours, including ovarian, breast and prostate carcinomas. The pharmacokinetic profile in humans at doses between 10 and 80 mg/m² is similar to that in animals, with one or two distribution phases: an initial phase with a half-life of 1–3 hours and a second phase with a half-life of 30–90 hours. The AUC after a dose of 50 mg/m² is approximately 300-fold greater than that with free drug. Clearance and volume of distribution are drastically reduced (at least 250-fold and 60-fold, respectively). Preliminary observations indicate that utilising the distinct pharmacokinetic parameters of pegylated liposomal doxorubicin in dose scheduling is an attractive possibility.

In agreement with the preclinical findings, the ability of pegylated liposomes to extravasate through the leaky vasculature of tumours, as well as their extended circulation time, results in enhanced delivery of liposomal drug and/or radiotracers to the tumour site in cancer patients. There is evidence of selective tumour uptake in malignant effusions, ARKS skin lesions and a variety of solid tumours.

The toxicity profile of pegylated liposomal doxorubicin is characterised by dose-limiting mucosal and cutaneous toxicities, mild myelosuppression, decreased cardiotoxicity compared with free doxorubicin and minimal alopecia. The mucocutaneous toxicities are dose-limiting per injection; however, the reduced cardiotoxicity allows a larger cumulative dose than that acceptable for free doxorubicin.

Thus, pegylated liposomal doxorubicin represents a new class of chemotherapy delivery system that may significantly improve the therapeutic index of doxorubicin.

Use of tradenames is for product identification only and does not imply endorsement.

Gregoriadis G. Targeting of drugs: implications in medicine. Lancet 1981; II: 241–6CrossRef

Juliano R, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975; 63: 651–8PubMedCrossRef

Poste G, Bucana C, Raz A, et al. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42: 1412–22PubMed

Hwang KJ, Padki MM, Chow DD, et al. Uptake of small liposomes by non-reticuloendothelial tissues. Biochim Biophys Acta 1987; 901: 88–96PubMedCrossRef

Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988; 85: 6949–53PubMedCrossRef

Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997; 11: 11–32

Gabizon A, Goren D, Cohen R, et al. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998; 53: 275–9PubMedCrossRef

Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996–1003PubMed

Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697–705PubMed

10.

Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424–36PubMedCrossRef

11.

Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171–99PubMedCrossRef

12.

Zalipsky S. Polyethylene glycol-lipid conjugates. In: Lasic D, Martin F, editors. Stealth liposomes. Boca Raton: CRC Press, 1995: 93–102

13.

Lasic D, Martin F, editors. Stealth liposomes. Boca Raton: CRC Press, 1995

14.

Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci 2001; 6: 66–77CrossRef

15.

Cullis PR, Hope MJ, Bally MB, et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997; 1331: 187–211PubMedCrossRef

16.

Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997; 24: 337–44CrossRef

17.

Wigler N, Inbar M, O’Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated lipsomal doxorubicin (Caelyx/Doxil) vs doxorubicin for first-line treatment of metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol (ASCO) 2002; 177

18.

Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001; 3: 156–62PubMedCrossRef

19.

Sharpe M, Easthope SE, Keating GM, et al. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS related Kaposi’s sarcoma. Drugs 2002; 62: 2089–126PubMedCrossRef

20.

Working PK, Dayan AD. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HC1). Hum Exp Toxicol 1996; 15: 751–85PubMed

21.

Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998; 95: 4607–12PubMedCrossRef

22.

Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363–80PubMedCrossRef

23.

Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752–6PubMed

24.

Lichtenberg D, Barenholz Y. Liposomes: preparation, characterization, and preservation. Vol 33. Glick D, editor. New York: Wiley, 1988

25.

Grant GJ, Barenholz Y, Piskoun B, et al. DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice. Pharm Res 2001; 18: 336–43PubMedCrossRef

26.

Lasic DD, Frederik PM, Stuart MC, et al. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett 1992; 312: 255–8PubMedCrossRef

27.

Lasic DD, Ceh B, Stuart MC, et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 145–56PubMedCrossRef

28.

Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201–15PubMedCrossRef

29.

Bolotin EM, Cohen R, Bar LK, et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 1994; 4: 455–79CrossRef

30.

Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992; 1109: 203–9PubMedCrossRef

31.

Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995; 16: 285–94CrossRef

32.

Bandak S, Goren D, Horowitz A, et al. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1999; 10: 911–20PubMedCrossRef

33.

Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83: 1029–37PubMedCrossRef

34.

Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10: 703–8PubMedCrossRef

35.

Amantea M, Newman MS, Sullivan TM, et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999; 18: 17–26PubMedCrossRef

36.

Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991; 1068: 133–41PubMedCrossRef

37.

Gabizon A, Tzemach D, Mak L, et al. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10: 539–48PubMedCrossRef

38.

Gabizon AA, Pappo O, Goren D, et al. Preclinical studies with doxorubicin encapsulated in polyethyleneglycol-coated liposomes. J Liposome Res 1993; 3: 517–28CrossRef

39.

Riggs Jr ER, Bachur R. Clinical pharmacokinetics of anthracycline antibiotics. In: Ames MM, Powis G, Kovach JS, editors. Pharmacokinetics of anticancer agents in humans. Amsterdam: Elsevier, 1983: 229–278

40.

Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–4PubMedCrossRef

41.

Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997; 54: 15–21PubMedCrossRef

42.

Working PK, Newman MS, Huang SK, et al. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil®). J Liposome Res 1994; 4: 667–87CrossRef

43.

Vaage J, Donovan D, Uster P, et al. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–6PubMedCrossRef

44.

Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73: 1478–84PubMedCrossRef

45.

Vaage J, Donovan D, Uster P, et al. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–6PubMedCrossRef

46.

Huang SK, Lee KD, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135–43PubMed

47.

Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352–6PubMed

48.

Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891–6PubMed

49.

Bally MB, Masin D, Nayar R, et al. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 1994; 34: 137–46PubMedCrossRef

50.

Gabizon A, Chemla M, Tzemach D, et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 1996; 3: 391–8PubMedCrossRef

51.

Hong RL, Huang CJ, Tseng YL, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999; 5: 3645–52PubMed

52.

Colbern GT, Hiller AJ, Musterer RS, et al. Significant increase in antitumor potency of doxorubicin HC1 by its encapsulation in pegylated liposomes. J Liposome Res 1999; 9: 523–38CrossRef

53.

Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–85PubMed

54.

Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567–71PubMed

55.

Working PK, Newman MS, Sullivan T, et al. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999; 289: 1128–33PubMed

56.

Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–92PubMed

57.

Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil®) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002; 8: 413–8PubMed

58.

Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001; 91: 1826–33PubMedCrossRef

59.

Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil®) in metastatic breast carcinoma. Cancer 2000; 89: 1037–47PubMedCrossRef

60.

Hamilton A, Biganzoli L, Coleman R, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 2002; 13: 910–8PubMedCrossRef

61.

Hubert A, Lyass O, Pode D, et al. Doxil® (Caelyx®): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000; 11: 123–7PubMedCrossRef

62.

Amantea MA, Forrest A, Northfelt DW, et al. Population pharmacokinetics and pharmacodynamics of pegylated-li-posomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 1997; 61: 301–11PubMedCrossRef

63.

Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36: 55–63PubMed

64.

Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9PubMed

65.

Gabizon A, Huang A, Martin F, et al. Doxorubicin encapsulated in polyethylene glycol-coated liposomes: initial clinical-pharmacokinetic studies in solid tumors. In: Lasic DD, Martin FJ, editors. Stealth liposomes. Boca Raton: CRC Press, 1995: 251–61

66.

Ranson MR, Carmichael J, O’Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185–91PubMed

67.

Toma S, Tucci A, Villani G, et al. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 2000; 20: 485–91PubMed

68.

Garcia AA, Kempf RA, Rogers M, et al. A phase II study of Doxil® (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 1998; 9: 1131–3PubMedCrossRef

69.

Gabizon AA, Muggia FM. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In: Woodle M, Storm G, editors. Long-circulating liposomes: old drugs, new therapeutics. Austin: Landes Bioscience, 1998: 165–74

70.

Lyass O, Hubert A, Gabizon AA. Phase I study of doxilcisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 2001; 7: 3040–6PubMed

71.

Northfelt DW. Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi’s sarcoma. Oncology 1997; 11: 21–32

72.

Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86: 72–8PubMedCrossRef

73.

Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243–54PubMed

74.

Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001; 91: 90–100PubMedCrossRef

75.

Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17: 3512–21PubMed

76.

Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000; 83: 1281–6PubMedCrossRef

77.

Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomasrationale for combination with radiotherapy. Acta Oncol 2000; 39: 207–11PubMedCrossRef

78.

Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029–33PubMedCrossRef

Title: Pharmacokinetics of Pegylated Liposomal Doxorubicin
Review of Animal and Human Studies
Authors: Alberto Gabizon
Hilary Shmeeda
Yechezkel Barenholz
Publication date: 01-04-2003
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 5/2003
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200342050-00002

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pharmacokinetics of Pegylated Liposomal Doxorubicin

Review of Animal and Human Studies

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2003

Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress

Transdermal Drug Delivery of Insulin with Ultradeformable Carriers

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

Aminoglycoside Dosages and Nephrotoxicity

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation